Using the right study materials can help strengthen the skills required to crack technical interviews in 2026. They aid in strengthening problem-solving skills, ...
In a hotel room in Santa Clara, Calif., five members of the AI company Anthropic huddled around a laptop, working urgently. It was February 2025, and they had been at a conference nearby when they ...
В Тюменской области полным ходом идет подготовка к единому дню голосования. Губернатор Александр Моор проинформировал полномочного ...
Предприниматели и чиновники Тюменской области и Югры ищут новые форматы взаимодействия. Представители Мегиона и Заводоуковска провели ...
We are approaching the integration of artificial intelligence into our universities in a piecemeal rather than a comprehensive fashion.
Here's Why. Ethereum remains a focal point for institutional on-chain activity even as price momentum stalls. In 2026, Ether has retreated about 36% for the year, slipping back from the $3,000 milesto ...
So you're spooked by a viral essay. How about, I don't know, looking at the data?
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Recursion Pharmaceuticals Inc. stock reached a new 52-week low, closing at $3.53, just pennies away from its absolute 52-week bottom of $3.54. This milestone marks a significant downturn for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results